product name Liproxstatin-1
Description: Liproxstatin-1 is a potent inhibitor of ferroptosis with IC50 value of 22 nM. Ferroptosis is a non-apoptotic form of cell death induced by small molecules in specific tumour types, and in engineered cells overexpressing oncogenic RAS. Liproxstatin-1 showed inhibition against ferroptosis-inducing agent (FIN) -triggered cell death. In Gpx4-/- cells, liproxstatin-1 inhibited RSL3-induced BODIPY 581/591 C11 oxidation.
References: Nat Cell Biol. 2014 Dec;16(12):1180-91.
340.85
Formula
C19H21ClN4
CAS No.
950455-15-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 68 mg/mL (199.5 mM)
Water: <1 mg/mL
Ethanol: 21 mg/mL (61.6 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19420331
| In Vitro |
In vitro activity: Liproxstatin-1 is able to inhibit ferroptosis in the low nanomolar range and inhibit the growth of Gpx4−/−cells with IC50 of 22 nM. Liproxstatin-1 (50 nM) completely prevents lipid peroxidation in Gpx4−/−cells. Liproxstatin-1 (200 nM) protects against FINs, such as BSO (10 µM), erastin (1 µM) and RSL3 (0.5 µM), in a dose dependent manner, whereas it fails to rescue cell death induced by staurosporine (0.2 µM) and H2O2 (200 µM). Kinase Assay: Cell Assay: Cell viability is assessed at different time points after treatment using AquaBluer according to the manufacturer’s recommendations. Alternatively, cell death is also quantified by measuring released lactate dehydrogenase activity using the cytotoxicity detection kit (LDH). |
|---|---|
| In Vivo | Liproxstatin-1 remarkably extends survival compared with the vehicle-treated group, delays ferroptosis in tubular cells, and mitigates tissue injury in ischaemia/reperfusion-induced liver injury. |
| Animal model | GreERT2; Gpx4fI/fI mice |
| Formulation & Dosage | Dissolved in % DMSO in PBS; 10 mg/kg; i.p. injection |
| References | Nat Cell Biol. 2014 Dec;16(12):1180-91. |
